Latest news

Milan, Italy, October 2026 – Adalvo is proud to announce that its Founder and CEO, Anil Okay, has been named CEO of the Year at the prestigious CPHI Awards 2026,...

New business unit brings together specialised scientific, regulatory and commercial expertise to support one of the industry's most advanced GLP-1 development platforms  Zug, Switzerland, 5 October 2026 – Adalvo...

Strengthening Adalvo's oncology portfolio with a targeted therapy for BRAF-mutated cancers. Zug, Switzerland, September 2026: Adalvo announced the submission of the Decentralised Procedure (DCP) for its generic Binimetinib 15...

Approval marks a significant regulatory milestone for Adalvo's pulmonary arterial hypertension programme and demonstrates the company's scientific and regulatory expertise. Zug, Switzerland, 24 September: Adalvo is pleased to announce...

A complex anti-infective developed and out-licensed by Adalvo achieves U.S. FDA approval, marking a major milestone in one of the market's most valuable anti-infective opportunities. Zug, Switzerland, 11 Sept 2026:...

Expanding Adalvo's presence in HIV therapies with one of the world's most widely prescribed HIV treatments.  Zug, Switzerland, 9 September: Adalvo announced the submission of its Decentralised Procedure (DCP)...

Building on a successful collaboration, Adalvo and Libbs extend their partnership to bring a high-quality, affordable central nervous system treatment to patients across Brazil. Zug, Switzerland, 31st August: Adalvo...

Adding to its first-to-market launch record, Adalvo delivers a simultaneous launch in all tablet strengths, on Day-1 of patent expiry, reaching patients the moment protection ends.  Zug, Switzerland, 24 August...

Adalvo, one of Europe’s leading B2B pharmaceutical companies, today announced the appointment of Anja Stapelfeld as Chief Human Resources Officer, effective immediately. The appointment reflects Adalvo’s continued investment in its...

Extending the company's dossier list in one of the most commercially relevant oral diabetes therapies in the global generics market.  Zug, Switzerland, 10 August 2026: Adalvo today announced the submission of...

Confirmed bioequivalence advances a complex haematology asset toward a global dossier and Day-1 launches across the US, EU and Rest of World.  Zug, Switzerland, 7 Aug 2026: Adalvo today announced...

An expanded co-development partnership, backed by shared investment, a resilient dual supply chain and cost leadership, positioning both companies at the forefront of one of the fastest-growing markets in medicine....

Milestone positions Adalvo as a global leader in one of the world's largest and fastest-growing markets for GLP-1 therapies, with Sandoz as commercial partner. Adalvo, one of Europe's leading B2B...

Parallel regulatory routes position a high-value rare disease asset for Day-1 launches across Europe.  Zug, Switzerland, 24th July 2026 — Adalvo today announced two regulatory milestones for its generic Tafamidis...

Results advance a high-value oncology asset towards regulatory submission and Day-1 launches across priority global markets, including the US.  Zug, Switzerland, 22nd July 2026 — Adalvo today announced positive results...

Switzerland, 20 July 2026 — Adalvo has entered into a partnership with humanitarian aid organization Direct Relief to expand access to essential medicines for underserved communities worldwide. The partnership marks...

As emergency relief efforts continue following the earthquake in Venezuela, Adalvo is supporting UNICEF’s work on the ground. At times like this, access to healthcare and essential support is critical....

Adalvo announces the first-to-market launch of generic Macitentan 10 mg film-coated tablets in Estonia, Latvia and Lithuania, in partnership with Norameda — the first generic version of the therapy available...